Resmetirom (Rezdiffra) for Fatty Liver: What Thyroid Patients Should Know

Resmetirom (Rezdiffra) is FDA-approved for MASH with significant fibrosis (F2–F3). It is a liver-selective thyroid hormone receptor-beta (TRβ) agonist — it lowers liver fat and improves fibrosis without affecting the heart, bone, or hypothyroid symptoms. It does not replace levothyroxine and is not a thyroid drug in the usual sense.

What resmetirom actually is

Resmetirom is a small molecule that selectively activates the thyroid hormone receptor beta (TRβ) subtype inside liver cells [C1][C3]. Thyroid hormone has two receptor subtypes throughout the body. TRα dominates in the heart, bone, and skeletal muscle and drives the heart-rate, temperature, and metabolic-rate effects you feel when thyroid hormone is high or low. TRβ dominates in the liver and the pituitary, where it controls cholesterol metabolism and fat-burning genes [C1].

Resmetirom takes advantage of that split. It is liver-targeted and TRβ-selective, so it turns on the liver's lipid-burning machinery without producing the cardiac, skeletal, or systemic hyperthyroid effects of regular thyroid hormone [C1][C3]. That is the entire design rationale: get the liver-fat benefit of thyroid hormone signaling, without the systemic hyperthyroidism that would happen if you simply raised T3 or T4.

It was approved by the FDA in March 2024 — the first drug ever approved specifically for MASH [C2][C3].

What MASH is, and why a thyroid receptor drug treats it

MASH stands for metabolic dysfunction-associated steatohepatitis — the new name for what used to be called NASH (non-alcoholic steatohepatitis), renamed in 2023 to better reflect the underlying metabolic biology [C5]. The bigger umbrella, MASLD (metabolic dysfunction-associated steatotic liver disease), is the new name for non-alcoholic fatty liver disease (NAFLD) [C5].

The progression looks like:

• MASLD — fat in the liver without much inflammation. Very common (~25–30% of adults).
• MASH — fat plus inflammation and liver-cell injury. About 20–30% of MASLD progresses to MASH [C5].
• Fibrosis (F0 simple → F4 cirrhosis) — scarring driven by chronic inflammation. F2–F3 is "significant" fibrosis without yet being cirrhotic [C2][C3].

Resmetirom is approved specifically for non-cirrhotic MASH with F2–F3 fibrosis — not for simple fatty liver, and not for cirrhosis [C2][C3]. In the MAESTRO-NASH phase 3 trial, both 80 mg and 100 mg daily doses produced higher rates of MASH resolution and fibrosis improvement on follow-up biopsy than placebo [C1][C2].

The thyroid–liver overlap (why this question comes up for you)

Hypothyroidism is a recognized driver of fatty liver. Low thyroid hormone slows hepatic fat oxidation, raises LDL, and shifts lipid handling toward storage — so untreated or under-treated hypothyroidism is associated with higher rates of MASLD and MASH [C1][C5]. Several converging factors pile up in Hashimoto's patients:

• Weight gain from low thyroid hormone increases liver fat.
• Insulin resistance commonly coexists.
• Many patients have metabolic syndrome features (high triglycerides, low HDL, central obesity).

This is why the question "will resmetirom help my Hashimoto's?" comes up at all — there is a real biological link between the two conditions [C1][C5]. But the link runs the other direction: fixing thyroid hormone may reduce liver fat. Resmetirom doesn't go upstream to fix thyroid hormone — it works downstream, in the liver.

Why it doesn't replace levothyroxine

Hypothyroid symptoms — fatigue, cold intolerance, slow heart rate, weight gain, hair loss, brain fog — are driven primarily by TRα signaling in the heart, brain, muscle, and skin [C6]. Resmetirom barely touches TRα. By design, it leaves the rest of your body's thyroid signaling unchanged [C1][C3].

That means:

• Resmetirom does not treat hypothyroidism.
• It does not raise your T3 or T4 levels in any clinically relevant systemic way.
• It does not allow you to reduce your levothyroxine dose.
• It is not a "natural thyroid booster," a weight-loss drug, or an energy supplement [C2][C3].

Your endocrinologist still manages your levothyroxine to target TSH; your hepatologist, if you have MASH F2–F3, separately manages the resmetirom decision [C6][C7].

Who is eligible

Per the FDA label and current reviews [C2][C3]:

• Adults with biopsy-confirmed or imaging-suggested MASH with F2 or F3 fibrosis.
• Not indicated for simple MASLD without significant fibrosis.
• Not indicated for cirrhosis (F4) — risk-benefit is unfavorable in decompensated disease.
• Not indicated for or studied in pregnancy.
• Standard liver chemistries, lipids, and TSH are checked at baseline and during follow-up [C3].

Eligibility is established by hepatology, often with FibroScan, MRI-PDFF, or biopsy [C5].

Side effects and monitoring

In the clinical trial program [C1][C2][C3]:

• Diarrhea and nausea are the most common side effects, usually mild and most prominent in the first weeks.
• Mild transient liver enzyme rises are seen in some patients and typically resolve.
• Theoretical risk of HPT-axis disturbance with long-term TRβ activation is monitored — current data show modest effects on TSH and free T4 assays that have not translated into clinically meaningful hypothyroid or hyperthyroid effects [C1][C3].

For thyroid patients specifically, the key practical point: resmetirom can modestly shift TSH and thyroid hormone lab values on peripheral assays without changing the underlying thyroid disease [C1][C3]. Your endocrinologist may interpret labs in context if you are on both medications, and dose decisions are made on the trend plus symptoms, not on a single number.

What does NOT help

A few things to set aside [C2][C6][C7]:

• Resmetirom is not a weight-loss drug. Modest weight loss in trials was secondary, not the primary endpoint, and not a basis for off-label use.
• It is not approved for or studied in Hashimoto's thyroiditis as a disease, hypothyroidism, hyperthyroidism, or thyroid eye disease.
• Buying it without a hepatology indication, or stopping levothyroxine in favor of it, is not supported by any evidence and risks both under-treated hypothyroidism and inappropriate liver drug exposure [C6][C7].

Practical guidelines

1. If you are concerned about fatty liver, start with labs and imaging. ALT/AST, lipid panel, and a FibroScan or ultrasound are reasonable first steps with your primary care or hepatologist [C5].
2. Make sure your hypothyroidism is well-treated first. TSH at target (often 0.5–2.5 mIU/L) is a basic baseline; under-treated hypothyroidism worsens liver fat [C6][C7].
3. Address the metabolic drivers. Weight, blood sugar, and lipid control reduce MASH progression and may avoid medication altogether [C5].
4. Resmetirom is a hepatology decision, not an endocrinology decision. If MASH with significant fibrosis is confirmed, the conversation happens with a liver specialist [C2][C3][C4].
5. Tell every prescriber about all your meds. Levothyroxine and resmetirom are managed in parallel, with periodic TSH and liver chemistry checks [C3][C6].

Frequently asked questions

Can resmetirom replace my levothyroxine? No. Resmetirom is TRβ-selective and liver-targeted; it does not correct hypothyroid symptoms, which depend on TRα signaling in the heart, brain, and muscle [C1][C6].

Will resmetirom help me lose weight? It is not a weight-loss drug. Weight effects in trials were small and not the indication [C2][C3].

I have fatty liver on ultrasound. Can I just ask for resmetirom? Probably not. The approval is for MASH with F2–F3 fibrosis, established by a hepatologist — not for simple steatosis [C2][C3][C5].

Could resmetirom affect my TSH or thyroid lab results? Modestly. Resmetirom can shift peripheral thyroid lab values without changing true thyroid function — your endocrinologist will interpret labs in context [C1][C3].

Is resmetirom safer than just taking thyroid hormone for fatty liver? Yes — that is the entire point of TRβ selectivity. Giving systemic thyroid hormone for liver fat would cause hyperthyroidism. Resmetirom isolates the liver effect [C1][C3].

Bottom line

Resmetirom (Rezdiffra) is the first FDA-approved drug for non-cirrhotic MASH with F2–F3 fibrosis and is a liver-selective TRβ agonist [C1][C2][C3]. It improves liver fat and fibrosis on biopsy without affecting the heart, bone, or hypothyroid symptoms [C1][C3]. It does not treat hypothyroidism, does not replace levothyroxine, and is not a thyroid booster or weight-loss drug [C2][C6][C7]. Fatty liver is genuinely more common in hypothyroidism — the right sequence is to confirm thyroid hormone is at target, address metabolic drivers, and let hepatology decide whether resmetirom fits your specific liver pathology [C4][C5][C6].

Sources

1. [C1] Liu M et al. A new liver-targeted agonist of thyroid hormone receptor beta resmetirom in treating MASLD/MASH: From mechanism to therapy. 2026. PubMed: 41964221
2. [C2] Bittla P et al. Resmetirom: A Systematic Review of the Revolutionizing Approach to Non-alcoholic Steatohepatitis Treatment Focusing on Efficacy, Safety, Cost-Effectiveness, and Impact on Quality of Life. 2024. PubMed: 39439647
3. [C3] Van Kleef LA et al. Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH). 2026. PubMed: 41868171
4. [C4] Alzaki AA et al. THR-β Agonists vs Incretin Therapies for Noncirrhotic MASH: A Biopsy-Anchored Systematic Review With GRADE Certainty. 2026. PubMed: 42051839
5. [C5] Vettor R et al. Overcoming the barriers in the screening, diagnosis, and follow-up of patients with MASLD and MASH. 2026. PubMed: 42090077
6. [C6] Jonklaas J et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670–1751. PubMed: 25266247
7. [C7] American Thyroid Association. Hypothyroidism — Patient Information. thyroid.org

---

For educational purposes only. Not medical advice. Always consult your healthcare provider.